Bernd C. Kieseier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Bernd C. Kieseier has a total of 295 co-authors. Here are the top co-authors by number of shared publications:
- Heinz Wiendl
From the Department of Neurology and Neuroscience, Medical Center and Faculty of Medicine, University of Freiburg, Germany
20 shared publications Hans-Peter Hartung
Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
19 shared publications- Hans-Peter Hartung
Department of Neurology, Medical Faculty Heinrich Heine University Düsseldorf Düsseldorf Germany
13 shared publications H.-P. Hartung
Klinik für Neurologie, Medizinische Fakultät, Heinrich-Heine Universität, Düsseldorf
9 shared publicationsClemens Warnke
From the Department of Neurology (C.W., T.D., K.W., V.I.L., H.-P.H., B.C.K.), Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; and Department of Clinical Neuroscience (R.R., C.H., N.N., T.O.), Karolinska Institute, Stockholm, Sweden
8 shared publicationsVerena I. Leussink
Heinrich-Heine University
8 shared publications
Latest Publications
- 3 August 2024
- Published by Springer Nature
- p. 829-843
Neuromuskuläre Erkrankungen bei Intensivpatienten
- 3 August 2024
- Published by Springer Nature
- p. 829-843
Neuromuskuläre Erkrankungen bei Intensivpatienten
- Open Access
- 26 May 2023
- Published by Springer Nature in BMC Neurology
- Vol. 23 (1) , 1-10
Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by progressive weakness and sensory loss, often affecting patient’s ability to walk and perform activities of daily living independently. Furthermore, patients often report fatigue and depression which can affect their quality of life. These symptoms were assessed in CIDP patients receiving long-term intravenous immunoglobulin (IVIG) treatment. GAMEDIS was a multi-center, prospective, non-interventional study in adult CIDP patients treated with IVIG (10%) and followed for two years. Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, Hughes Disability Scale (HDS), Fatigue Severity Scale (FSS), Beck Depression Inventory II (BDI), Short Form-36 health survey (SF-36) and Work Productivity and Activity Impairment Score Attributable to General Health (WPAI-GH) were assessed at baseline and quarterly. Dosing and treatment intervals, changes in outcome parameters, and adverse events (AEs) were analyzed. 148 evaluable patients were followed for a mean of 83.3 weeks. The mean maintenance IVIG dose was 0.9 g/kg/cycle (mean cycle interval 38 days). Disability and fatigue remained stable throughout the study. Mean INCAT score: 2.4 ± 1.8 at baseline and 2.5 ± 1.9 at study end. HDS: 74.3% healthy/minor symptoms at baseline and 71.6% at study end. Mean FSS: 4.2 ± 1.6 at baseline and 4.1 ± 1.7 at study end. All patients reported minimal/no depression at baseline and throughout. SF-36 and WPAI-GH scores remained stable. Fifteen patients (9.5%) experienced potentially treatment-related AEs. There were no AEs in 99.3% of infusions. Long-term treatment of CIDP patients with IVIG 10% in real-world conditions maintained clinical stability on fatigue and depression over 96 weeks. This treatment was well-tolerated and safe.
- 26 May 2023
- Published by Springer Nature in BMC Neurology
- Vol. 23 (1) , 1-10
Open AccessFatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by progressive weakness and sensory loss, often affecting patient’s ability to walk and perform activities of daily living independently. Furthermore, patients often report fatigue and depression which can affect their quality of life. These symptoms were assessed in CIDP patients receiving long-term intravenous immunoglobulin (IVIG) treatment. GAMEDIS was a multi-center, prospective, non-interventional study in adult CIDP patients treated with IVIG (10%) and followed for two years. Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, Hughes Disability Scale (HDS), Fatigue Severity Scale (FSS), Beck Depression Inventory II (BDI), Short Form-36 health survey (SF-36) and Work Productivity and Activity Impairment Score Attributable to General Health (WPAI-GH) were assessed at baseline and quarterly. Dosing and treatment intervals, changes in outcome parameters, and adverse events (AEs) were analyzed. 148 evaluable patients were followed for a mean of 83.3 weeks. The mean maintenance IVIG dose was 0.9 g/kg/cycle (mean cycle interval 38 days). Disability and fatigue remained stable throughout the study. Mean INCAT score: 2.4 ± 1.8 at baseline and 2.5 ± 1.9 at study end. HDS: 74.3% healthy/minor symptoms at baseline and 71.6% at study end. Mean FSS: 4.2 ± 1.6 at baseline and 4.1 ± 1.7 at study end. All patients reported minimal/no depression at baseline and throughout. SF-36 and WPAI-GH scores remained stable. Fifteen patients (9.5%) experienced potentially treatment-related AEs. There were no AEs in 99.3% of infusions. Long-term treatment of CIDP patients with IVIG 10% in real-world conditions maintained clinical stability on fatigue and depression over 96 weeks. This treatment was well-tolerated and safe.
- 8 November 2022
- Published by Springer Nature
- p. 1-16
Neuromuskuläre Erkrankungen bei Intensivpatienten
- 5 December 2019
- Published by Springer Nature in Der Nervenarzt
- Vol. 90 (12) , 1205-1206
Patientenmonitoring 4.0
- 5 December 2019
- Published by Springer Nature in Der Nervenarzt
- Vol. 90 (12) , 1205-1206
Patientenmonitoring 4.0
- 11 October 2018
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 4 (1) , 31
Immune-mediated neuropathies
Since the discovery of an acute monophasic paralysis, later coined Guillain–Barré syndrome, almost 100 years ago, and the discovery of chronic, steroid-responsive polyneuropathy 50 years ago, the spectrum of immune-mediated polyneuropathies has broadened, with various subtypes continuing to be identified, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN). In general, these disorders are speculated to be caused by autoimmunity to proteins located at the node of Ranvier or components of myelin of peripheral nerves, although disease-associated autoantibodies have not been identified for all disorders. Owing to the numerous subtypes of the immune-mediated neuropathies, making the right diagnosis in daily clinical practice is complicated. Moreover, treating these disorders, particularly their chronic variants, such as CIDP and MMN, poses a challenge. In general, management of these disorders includes immunotherapies, such as corticosteroids, intravenous immunoglobulin or plasma exchange. Improvements in clinical criteria and the emergence of more disease-specific immunotherapies should broaden the therapeutic options for these disabling diseases.
- 11 October 2018
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 4 (1) , 31
Immune-mediated neuropathies
Since the discovery of an acute monophasic paralysis, later coined Guillain–Barré syndrome, almost 100 years ago, and the discovery of chronic, steroid-responsive polyneuropathy 50 years ago, the spectrum of immune-mediated polyneuropathies has broadened, with various subtypes continuing to be identified, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN). In general, these disorders are speculated to be caused by autoimmunity to proteins located at the node of Ranvier or components of myelin of peripheral nerves, although disease-associated autoantibodies have not been identified for all disorders. Owing to the numerous subtypes of the immune-mediated neuropathies, making the right diagnosis in daily clinical practice is complicated. Moreover, treating these disorders, particularly their chronic variants, such as CIDP and MMN, poses a challenge. In general, management of these disorders includes immunotherapies, such as corticosteroids, intravenous immunoglobulin or plasma exchange. Improvements in clinical criteria and the emergence of more disease-specific immunotherapies should broaden the therapeutic options for these disabling diseases.
- 9 February 2018
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 115 (6) , 81-82
Progress in Recognizing and Treating Polyneuropathy
Polyneuropathies represent a common group of diseases exhibiting a wide variety of symptoms that are encountered by treating physicians across virtually all specialties in hospitals and practices. They are disorders of the peripheral nervous system...
- 9 February 2018
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 115 (6) , 81-82
Progress in Recognizing and Treating Polyneuropathy
Polyneuropathies represent a common group of diseases exhibiting a wide variety of symptoms that are encountered by treating physicians across virtually all specialties in hospitals and practices. They are disorders of the peripheral nervous system...
- 8 September 2016
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 43 (07) , 441-451
Aktuelle Therapie von Immunneuropathien
Seit der Erstbeschreibung einer akuten monophasisch verlaufenden peripheren Lähmung vor genau 100 Jahren, dem Guillain-Barré Syndrom (GBS), dauerte es nochmals 42 Jahre, bis eine chronische, Kortikosteroid-responsive Polyneuropathie erstmalig beschrieben wurde. Seither hat sich das Spektrum der Immunneuropathien stetig erweitert und noch immer werden einzelne Subformen neu definiert. Die Behandlung immunvermittelter Polyneuropathien, insbesondere chronisch verlaufender Varianten, wie die chronisch inflammatorische (entzündliche) demyelinisierende Polyneuropathie (CIDP) sowie die multifokal motorische Neuropathie (MMN), stellt im klinischen Alltag eine Herausforderung dar. Aufgrund ihrer klinischen Heterogenität und geringen Prävalenzen gibt es nur wenige Therapiestudien höchster Evidenzklasse, die eine eindeutige Empfehlung ermöglichen. Aktuelle Fortschritte in der Klassifikation mittels neuer diagnostischer Kriterien sowie die rapide Zunahme moderner Immuntherapeutika in der Neurologie lassen hoffen, dass eine verbesserte Klassifikation und ein breiteres therapeutisches Repertoire für den klinischen Alltag in Zukunft zur Verfügung stehen werden. In dem folgenden Übersichtsartikel werden die aktuellen Empfehlungen sowie neusten Entwicklungen auf dem Therapiesektor zur Behandlung akuter als auch chronischer Immunneuropathien dargestellt. Since the first description of an acute monophasic paralysis 100 years ago, later designated as the Guillain-Barré syndrome (GBS), another 42 years passed before a chronic, steroid-responsive polyneuropathy was reported. Since then, the spectrum of immune-mediated polyneuropathies has been broadened and different subforms have been identified. In daily clinical practice, treating immune-mediated neuropathies, especially its various chronic variants, such as the chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or the multifocal motor neuropathy (MMN), represents a challenge. The large clinical heterogeneity and the low prevalence of these different neuropathies are reasons for the very few clinical trials of high scientific standard offering therapeutic recommendations based on highest clinical evidence. As such, it is hoped that with better clinical criteria and the emergence of modern immunotherapies, the therapeutic armamentarium against these disabling disease might be broadened in the future. This review article summarizes current treatment recommendations for acute as well as chronic immune-mediated neuropathies.
- 8 September 2016
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 43 (07) , 441-451
Aktuelle Therapie von Immunneuropathien
Seit der Erstbeschreibung einer akuten monophasisch verlaufenden peripheren Lähmung vor genau 100 Jahren, dem Guillain-Barré Syndrom (GBS), dauerte es nochmals 42 Jahre, bis eine chronische, Kortikosteroid-responsive Polyneuropathie erstmalig beschrieben wurde. Seither hat sich das Spektrum der Immunneuropathien stetig erweitert und noch immer werden einzelne Subformen neu definiert. Die Behandlung immunvermittelter Polyneuropathien, insbesondere chronisch verlaufender Varianten, wie die chronisch inflammatorische (entzündliche) demyelinisierende Polyneuropathie (CIDP) sowie die multifokal motorische Neuropathie (MMN), stellt im klinischen Alltag eine Herausforderung dar. Aufgrund ihrer klinischen Heterogenität und geringen Prävalenzen gibt es nur wenige Therapiestudien höchster Evidenzklasse, die eine eindeutige Empfehlung ermöglichen. Aktuelle Fortschritte in der Klassifikation mittels neuer diagnostischer Kriterien sowie die rapide Zunahme moderner Immuntherapeutika in der Neurologie lassen hoffen, dass eine verbesserte Klassifikation und ein breiteres therapeutisches Repertoire für den klinischen Alltag in Zukunft zur Verfügung stehen werden. In dem folgenden Übersichtsartikel werden die aktuellen Empfehlungen sowie neusten Entwicklungen auf dem Therapiesektor zur Behandlung akuter als auch chronischer Immunneuropathien dargestellt. Since the first description of an acute monophasic paralysis 100 years ago, later designated as the Guillain-Barré syndrome (GBS), another 42 years passed before a chronic, steroid-responsive polyneuropathy was reported. Since then, the spectrum of immune-mediated polyneuropathies has been broadened and different subforms have been identified. In daily clinical practice, treating immune-mediated neuropathies, especially its various chronic variants, such as the chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or the multifocal motor neuropathy (MMN), represents a challenge. The large clinical heterogeneity and the low prevalence of these different neuropathies are reasons for the very few clinical trials of high scientific standard offering therapeutic recommendations based on highest clinical evidence. As such, it is hoped that with better clinical criteria and the emergence of modern immunotherapies, the therapeutic armamentarium against these disabling disease might be broadened in the future. This review article summarizes current treatment recommendations for acute as well as chronic immune-mediated neuropathies.
- 8 April 2016
- Published by Springer Nature in Journal of Neurology
- Vol. 263 (5) , 1027-1028
Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of ‘Chinese restaurant syndrome’
- 8 April 2016
- Published by Springer Nature in Journal of Neurology
- Vol. 263 (5) , 1027-1028
Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of ‘Chinese restaurant syndrome’
- Open Access
- 16 September 2015
- Published by Wiley in European Journal of Neurology
- Vol. 22, 1-2
Multiple sclerosis - a dynamic field with a need for excellent education
- 16 September 2015
- Published by Wiley in European Journal of Neurology
- Vol. 22, 1-2
Open AccessMultiple sclerosis - a dynamic field with a need for excellent education